12:00 AM
Feb 25, 2002
 |  BioCentury  |  Product Development

Pharmacogenetics might have helped

Sugen Inc. believes its semanaxib small molecule VEGFR2 (Flk-1/KDR) antagonist failed to increase survival and tumor progression times in a Phase III trial in colorectal cancer patients earlier this month due to its pharmacokinetic profile. But research published by ImClone Systems Inc. last week suggests that tumor heterogeneity could have affected patient outcomes as well.

Laura Shawver, president and CEO of Sugen Inc., the subsidiary of Pharmacia Corp. (PHA, Peapack, N.J.) that was developing semanaxib (SU5416), told BioCentury that Sugen believes semanaxib failed for pharmacokinetic reasons. According to Shawver, the half life of semanaxib is only one hour, though pharmacodynamic studies in cultured endothelial...

Read the full 520 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >